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Summary Twelve patients were treated with didox, a new ribonucleotide reductase inhibitor, by 36 h
infusion. The maximum tolerated dose was 6 g m2, above which dose-limiting hepatic toxicity was observed.
Patient tolerance was significantly better using the 36 h infusion compared to patients receiving the drug by a
30 min infusion; in particular, there were no reports of nausea or vomiting. No responses were seen in these
patients. Detailed pharmacokinetics were performed at 6 g m-2 comparing the 36 h and 30 min infusions in
four patients. Parent drug AUC values were lower for the 36 h infusion, 67.8 fig ml- h- compared to
232 jig ml-' h-' for the 30 min infusion. AUC values for the 3-hydroxy metabolite were much higher following
the 36 h infusion: 55.4 compared to 18.6 ig ml' h-'. In contrast, the amide metabolite was not detected
following the 36 h infusion, but AUC values of 23 jig ml- ' h-' were seen after the 30 min infusion. The mean
peak plasma level was 72 fig ml-' following 6 g m2 given by a 30 min infusion compared to 2.8 jLg ml'
following the prolonged infusion. Clearance was higher following the 36 h infusion: 97.6 versus 24.4 1 h-'.
The enzyme ribonucleotide reductase provides an excellent
target for anti-cancer drugs in view of the importance of the
production of deoxyribonucleotides for DNA synthesis
(Elford et al., 1981). The enzyme is known to have low
activity in resting cells, and increasing with proliferation
(Elford et al., 1970), with the level of the enzyme correlated
with the rate of replication (Turner et al., 1968).
Hydroxyurea is a specific inhibitor of ribonucleotide reduc-
tase (Thurman, 1964) and is the only inhibitor available
clinically at present, although it is a relatively weak inhibitor
of the enzyme in vitro (Elford, 1968). Recently, many
hydroxyurea analogues have been tested in vivo and in vitro
with didox (N, 3-4 trihydroxybenzamide) exhibiting activity
in L1210 leukaemia bearing mice (van't Riet et al., 1979) and
in the NCI tumour panel (Elford & van't Riet, 1985).
Didox causes greater inhibition of the target enzyme
(Elford et al., 1979) and in view of its in vivo activity was
entered in phase I evaluation, as part of a co-ordinated
programme under the aegis of the Cancer Research Cam-
paign Phase I/II Clinical Trials Committee. It was initially
administered by intravenous infusion over 30 min (Veale et
al., 1988b). Dose limiting toxicity was predominantly hepatic
in these patients and was seen at doses of 7 g m-2 and above.
However, at doses greater than 2.3 gm2 significant gast-
rointestinal toxicity was observed, with severe nausea, vom-
iting and diarrhoea seen in some patients. The recommended
maximum tolerated dose was therefore 6 g m-2. Hydroxyurea
has been given safely by infusion over 24-36 h infusion
(Veale et al., 1988a), and didox was therefore administered
by 36 h infusion in a phase I study in an attempt to cause
more prolonged inhibition of ribonucleotide reductase. De-
tailed pharmacokinetics were performed at 6 gm2 compar-
ing both 36 h and 30 min infusions.
Patients and methods
Patients with histologically proven metastatic malignant di-
sease who had either failed first line chemotherapy or for
whom no conventional treatment existed, were entered into
this study. All patients had normal renal and liver function
and were of good performance status (ECOG 0-2; WHO,
1979). Patients had received no other cytotoxic chemotherapy
for I month before the study.
As the maximum tolerated dose for the slow i.v. injection
was 6 g m-2 (Veale et al., 19886), infusional didox treatment
commenced at a dose of 2.5 gm-2. The dose was then in-
creased to s g5m2 and subsequently by 1 g m2 increments.
Didox was dissolved in 3 litres of 0.5 N dextrose saline and
given as a continuous infusion over 36 h. For the com-
parative pharmacokinetic study, slow intravenous injections
were given at a dose of 6 gm-2 in 500 ml 0.5N dextrose
saline over 30 min, with patients randomly receiving either
the slow i.v. injection or 36 h infusion on alternate courses.
Patients were treated every 3 weeks, with a minimum of three
patients treated at each dose increment.
Pharmacokinetics
Blood samples were taken from an indwelling catheter at the
following times: (a) 30min infusion: pre-treatment, 15 and
30 min, then 5, 15, 30, 60 min, 2, 4, 6, 8 and 24 h post-
infusion; (b) 36 h infusion: pre-treatment, 0.5, 1, 1.5, 2, 6, 12,
24, 36 h, then 5, 15, 30, 60 min, 2, 4, 6 and 8 h post-infusion.
Urine was collected and aliquoted pre-treatment and sub-
sequently every 6 h during and post-treatment up to 12 h
following completion of treatment.
Analytical methods
Didox levels were measured in plasma and urine by HPLC
using a Beckman/Altex IOOA pump and stainless steel col-
umn (15 cm x 0.46 cm) packed with a A-Bondapack C18,
10 jim particle size, as previously described (Veale et al.,
1988). Metabolites were identified using standards supplied
by Elford. In order to resolve didox and its metabolites from
interfering substances in plasma the following step-gradient
system was employed: (1) 0.1 M sodium phosphate pH 6.0 for
2 min; (2) as above + 2% acetonitrile pH 6.0 for 2 min; (3)
as above + 5% acetonitrile pH 6.0 for 4 min; (4) as above
+ 10% acetonitrile pH 6.0 for 0.5 min; (5) as above + 20%
acetonitrile pH 6.0 for 0.5 min; (6) as above + 30% acetonit-
rile pH 6.0 for 10 min. The column was equilibrated with
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buffer 1 for 7 min before loading the next sample.
Retention times of 4 min, 7.78 min, 9.5 min, 10.45 min and
12.86 min were observed for didox, amide, 3-OH, 3-MeO and
I.S. respectively. Extraction efficiency was 80%, 82%, 95%,
94% for didox, amide, 3-hydroxy and 3-methoxy meta-
bolites, with a detection limit of 100 ng for each compound.
Urine samples were injected directly onto the column and
eluted isocratically with 0.1 M sodium phosphate pH 6.0. The
resolution of metabolites in urine was not possible due to the
large number of interfering substances.
The area under the plasma concentration-time curve
(AUC) was calculated by the log trapezoidal rule with ext-
rapolation to infinity. As the drug was proven subsequently
to have non-linear pharmacokinetics, it was not deemed
logical to fit the data to linear compartmental models. Drug
clearance was calculated using the expression:
dose
Clearance =
AUC
Results
Patient details are shown in Table I. In the 36 h infusion
dose escalation study, three patients received 2.5 g m-2, three
5 g m-2, ten 6 g m-2, and two 7 g m-2 of didox. In addition,
five patients were treated at 6 g m-2 as a 30 min infusion as
part of the comparative pharmacokinetic study. No responses
were seen at any dose level.
Details of toxicity are shown in Table II. No toxicity was
seen with the infusion up to 6 gm2. At 6 gm-2 grade 1
hepatotoxicity was seen in two of 10 patients and grade 2
toxicity in one patient, but these abnormalities were rapidly
reversible. At 7 g m-2 grade 1 hepatotoxicity was seen in one
patient and grade 3 hepatotoxicity in the other patient. This
toxicity was considered dose-limiting, with the maximum
tolerated dose therefore 6 g m-2. Gastrointestinal toxicity
was absent up to a dose of 7 g m2. Side-effects following the
30 min infusion are shown in Table II, relating to the 6 g m-2
dose. Gastrointestinal toxicity was severe, with grade 3 nau-
sea and vomiting in three of five patients, and minor hepat-
otoxicity observed in three patients.
Four patients received two courses at 6 g m2, one by
30min and the other as a 36h infusion. Pharmacokinetic
profiles for these patients illustrated in Figure 1, with the
various parameters summarised in Table III. Two other
patients received only one course of didox (6 g m-2), one as a
30 min and the other as a 36 h infusion. The mean AUC
value (± s.e.m.) for the parent drug following the 30 min
infusion was significantly higher (282 ± 60 versus
68 ± 11 ,ug ml-' h-'). In contrast, AUC levels for the 3-
hydroxy metabolite of didox were significantly higher follow-
ing the prolonged infusion (55.4 ± 3.2 versus
18.6 ± 2.6 Lg ml-' h-'). Significant levels of the amide met-
abolite of didox were observed following the 30 min infusion,
but this metabolite was not detected following the prolonged
infusion. End of infusion peak plasma didox levels of 72 ± 5
and 2.8 ± 0.6jig ml-' were seen following the short and pro-
longed infusions respectively, with steady state didox levels of
1.8 fig ml-' achieved during the latter. Clearance values were
Table I Patient characteristics
Number of patients 12
Male: female 5:7
Age (range) 49.8 (39-72)
Previous chemotherapy 11
Histology
Sarcoma 3
Melanoma 3
Colon 2
Mesothelioma I
Breast I
Small cell lung cancer I
Ovary I
Table II Toxicity of didox administered either by a 30min or 36 h
infusion
Drug dose Toxicity (WHO grade)
Symptom (mgm-2) No. pts 1 2 3 4
36 h infusion
Nausea and 2500 3
vomiting 5000 3
6000 10 - -
7000 2 - - I -
LFTs
Bilirubin <5000 6
6000 10 - - -
7000 2 - I -
AST <5000 6 - - -
6000 10 3 - -
7000 2 1 -
Alk. phos. <5000 6 - -
6000 10 2 1 -
7000 2 -
Pain 7000 2 -
30 min infusion
Nausea and 6000 5 1 3
vomiting
LFTs
Bilirubin 6000 5 1
AST 6000 5 2 1 -
Alk. phos. 6000 5 2 1 -
much higher following the prolonged infusion (98 ± 14 versus
24 ± 41 h-'). Following the 30 min infusion 12.4% of the
didox was excreted unchanged in the urine within 24 h, with
only 5% of unchanged drug recovered following the pro-
longed infusion. Interfering peaks were observed in the urine
where the didox metabolites were expected, therefore the
level of urinary excretion of didox metabolites could not be
determined.
Discussion
A phase 1 study of didox, administered as a 36 h infusion,
was performed in 12 patients. Toxicity was minimal up to
6 g m-2 when minor hepatotoxicity was observed, with severe
hepatotoxicity noted in one of the two patients treated at
7gm-2. No myelosuppression was seen at any dose level.
Gastrointestinal toxicity was severe with the short injection
at 6gm-2, although minor hepatotoxicity was also noted.
The recommended maximum tolerated dose for both routes
of administration was 6 gm2, although the toxicity profile
was different for the two modes of administration. Despite
marked differences in pharmacokinetics and drug metabolism
between the injection and infusion, the maximum tolerated
dose of the drug was the same, with hepatotoxicity dose-
limiting in both. However, the prolonged infusion was
significantly better tolerated and in particular gastrointestinal
toxicity was rare.
In a previous study (Veale et al., 1988b) didox was given as
a short injection in doses up to 10 gm2. Pharmacokinetics
were performed at 1,728 mgm2 in that study, showing a-
half life of 5.2 min, P-half life of 41.3 min and clearance of
42.6 ± 11.4 1 h-1. Although the infusion rates were different
in both studies (short infusion versus 30 min) this is unlikely
to produce a difference in pharmacokinetics and was ac-
counted for in calculations. Thus clearance showed a marked
difference between the two different doses. It is possible that
the pharmacokinetics of didox are non-linear as drug clear-
ance is dose-dependent. The ideal way to test this hypothesis
is by performing pharmacokinetic studies at each dose level
for a schedule, but this was not performed in the present
study.
Clearance was also schedule-dependent. It is possible that
the increase in clearance of the parent drug seen on increas-
ing the duration of infusion from 0.5 to 36 h could be related
to induction of its own metabolism, but this would not
explain the reduction in clearance caused by increasing drugSTUDY OF DIDOX 449
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Figure 1 Pharmacokinetic profile in 4 patients receiving didox by (a) 36 h infusion and (b) 30 min infusion. The arrows indicate
the completion of the infusion. 0 didox, * 3-hydroxy, amide, -0 3-methoxy.
Table III Pharmacokinetic details of six patients treated with didox at a dose of 6 gm-2, by 30 min or 36 h infusion
Treatment Area under curve (AUC) 24 h urinary Plasma conc.
duration (pg ml-'h') C,, x Clearance excretion steady state
Patient (h) PD Amide 3-Hydroxy (jagml-') (Ih-) (% total) (pgml')
1 0.5 198 17 20 72 30.3 18% -
36 53 - 57 2.55 113 - 1.4
2 0.5 174 15 18 61 34.5 1.6% -
36 58 - 49 2.0 103 - 1.47
3 36 43 - 47 1.38 140 - 1.16
4 0.5 509 43 9.1 67 11.8 13.3% -
36 80 - 61 3.5 75 - 2.3
5 0.5 240 16 23 91 25 - -
6 0.5 290 24 23 69 20.7 9.3% -
36 105 - 63 4.8 57 - 2.8
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dose administered by similar infusion rates. Similarly, the
rapid appearance of the amide metabolite within 30 min of
the bolus, and the high proportion of 3-hydroxy metabolite
within 2 h of starting the infusion, make induced metabolism
unlikely.
Interesting differences in the pattern of metabolism were
noted on comparing the two infusion rates at 6 g m2.
Higher AUC values were seen for the parent drug following
the short infusion but higher AUC values for the 3-hydroxy
metabolite following the prolonged infusion. An amide met-
abolite was only detectable following the 30 min infusion.
The higher AUC value, higher peak plasma level, lower
clearance and altered metabolic profile following the 30 min
infusion are suggestive, but not conclusive, that there is
saturable hepatic metabolism of didox, with greater produc-
tion of the 3-hydroxy metabolite when given by the pro-
longed infusion. Despite these differences in metabolism and
pharmacokinetics, the maximum tolerated dose and hepato-
toxicity were similar for both infusional rates. Differences in
gastrointestinal toxicity may be attributable to the higher
peak plasma levels of didox observed following the short
infusion. As previously stated, the urinary excretion data is
incomplete, as multiple interfering peaks were observed in
urine where the metabolite peaks were expected. Therefore,
the contribution of various metabolites to total urinary excre-
tion could not be adequately assessed.
Steady state plasma levels of didox of 2.8 ± 1.3 tg ml'
were therefore achieved during the 36 h infusion. These levels
are slightly lower than those shown to be active in experi-
mental models. In an enzyme study 8.4figml-' didox was
shown to cause 50% inhibition of ribonucleotide reductase,
and levels of less than 30ggml-' have been growth inhib-
itory in vitro using a variety of cell lines. Peak achievable
plasma levels are, therefore, significantly lower than the levels
of didox shown to be effective in vitro. However, the develop-
ment of toxicity suggests either the metabolites are active, or
there are other mechanisms of action in vivo.
The maximum tolerated dose of didox has been shown to
be 6 g m-2 by two different schedules. The choice of optimal
schedule remains debatable, although the cytostatic activity
of didox is related to both the concentration ofdrug achieved
and the duration of exposure. Although Cmax was higher with
the short infusion, levels considered adequate to block ribo-
nucleotide reductase were achieved for only a short period.
Clearly, it would be possible to design a loading dose/
constant infusion schedule using an intermediate infusion
duration that would result in higher steady state levels, albeit
for a shorter time. In general, anti-metabolites or drugs
acting on S phase targets are more effective given over the
duration of a cell cycle rather than for a much shorter period
of time. As there was no myelotoxicity observed in these
studies, it may be possible to administer didox more fre-
quently than described in this particular schedule, although
this would need to be evaluated in a further study. However,
this schedule represents the tolerable dose over 36 h and
represents a rational duration of infusion, based on our
previous data with the S phase specific ribonucleotide reduc-
tase inhibitor hydroxyurea (Veale et al., 1988a).
No responses were seen in this study, although a limited
number of patients with refractory tumours were treated.
Whether the lack of clinical response relates to the refractory
nature of the tumours treated or to the inadequate plasma
levels achieved in this study remains unanswered. However, it
is intended to carry out a phase II study of didox in patients
with breast cancer in the near future, to determine clinical
anti-tumour activity.
Didox was supplied through the CRC Phase I Committee and we are
grateful to Dr B. van't Riet for synthesis of the drug and Dr R.
Vezin, Strathclyde University, for its formulation. We would like to
thank the nursing staff of the Radiotherapy Department, Newcastle
General Hospital for their help and Ms Christine Rivett and the
Pharmacy Department for preparing the didox infusions.
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